Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen

Схожие документы

• The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients
  по: Khandelwal, Pooja, et al.
  Опубликовано: (2013)
• An Intermediate Alemtuzumab Schedule Reduces the Incidence of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
  по: Marsh, Rebecca A., et al.
  Опубликовано: (2013)
• A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation
  по: Khandelwal, Pooja, et al.
  Опубликовано: (2016)
• Veno-Occlusive Disease of the Liver in the Absence of Elevation in Bilirubin in Pediatric Patients after Hematopoietic Stem Cell Transplantation
  по: Myers, Kasiani C., et al.
  Опубликовано: (2014)
• Comparison of graft versus host disease with three different alemtuzumab schedules in unrelated donor fludarabine and melphalan allografts
  по: Green, Kile, et al.
  Опубликовано: (2017)